These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16194710)

  • 1. Biological considerations in the assessment of urothelial cancer: a retrospective.
    Droller MJ
    Urology; 2005 Nov; 66(5 Suppl):66-75. PubMed ID: 16194710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular markers for bladder cancer: the road to a multimarker approach.
    Birkhahn M; Mitra AP; Cote RJ
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1717-27. PubMed ID: 18062746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
    Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
    J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.
    Mitra AP; Datar RH; Cote RJ
    J Clin Oncol; 2006 Dec; 24(35):5552-64. PubMed ID: 17158541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological pathways to bladder carcinogenesis.
    Gonzalgo ML; Schoenberg MP; Rodriguez R
    Semin Urol Oncol; 2000 Nov; 18(4):256-63. PubMed ID: 11101088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer.
    Streeper NM; Simons CM; Konety BR; Muirhead DM; Williams RD; O'Donnell MA; Joudi FN
    BJU Int; 2009 Feb; 103(4):475-9. PubMed ID: 18990174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular changes in development and progression of urothelial carcinoma].
    Hartmann A
    Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular genetics of bladder cancer: targets for diagnosis and therapy.
    Baffa R; Letko J; McClung C; LeNoir J; Vecchione A; Gomella LG
    J Exp Clin Cancer Res; 2006 Jun; 25(2):145-60. PubMed ID: 16918124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of muscle-invasive bladder cancer in Victoria, 1990-1995.
    Millar JL; Frydenberg M; Toner G; Syme R; Thursfield V; Giles GG;
    ANZ J Surg; 2006 Mar; 76(3):113-9. PubMed ID: 16626343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmacytoid urothelial carcinoma of the bladder.
    Lopez-Beltran A; Requena MJ; Montironi R; Blanca A; Cheng L
    Hum Pathol; 2009 Jul; 40(7):1023-8. PubMed ID: 19297008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging.
    Sugano K; Kakizoe T
    Nat Clin Pract Urol; 2006 Dec; 3(12):642-52. PubMed ID: 17149381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic biomarkers in urothelial bladder cancer.
    Kim WJ; Kim YJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavior of urothelial carcinoma with respect to anatomical location.
    Catto JW; Yates DR; Rehman I; Azzouzi AR; Patterson J; Sibony M; Cussenot O; Hamdy FC
    J Urol; 2007 May; 177(5):1715-20. PubMed ID: 17437794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers.
    Novara G; De Marco V; Gottardo F; Dalpiaz O; Bouygues V; Galfano A; Martignoni G; Patard JJ; Artibani W; Ficarra V
    Cancer; 2007 Oct; 110(8):1715-22. PubMed ID: 17724728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bladder cancer: modeling and translation.
    Rosenberg JE; Hahn WC
    Genes Dev; 2009 Mar; 23(6):655-9. PubMed ID: 19299556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter hypermethylation identifies progression risk in bladder cancer.
    Yates DR; Rehman I; Abbod MF; Meuth M; Cross SS; Linkens DA; Hamdy FC; Catto JW
    Clin Cancer Res; 2007 Apr; 13(7):2046-53. PubMed ID: 17404085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.
    Denzinger S; Mohren K; Knuechel R; Wild PJ; Burger M; Wieland WF; Hartmann A; Stoehr R
    Hum Pathol; 2006 Feb; 37(2):143-51. PubMed ID: 16426913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.